Renal morbidity in type 2 diabetes mellitus patients with and without non-alcoholic fatty liver disease

Tanuku Vivek; Shimpa R. Sharma

doi:10.18203/2320-6012.ijrms20230570

Authors

Tanuku Vivek Department of General Medicine, D.Y Patil Medical College, Kolhapur, Maharashtra, India
Shimpa R. Sharma Department of General Medicine, D.Y Patil Medical College, Kolhapur, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20230570

Keywords:

NAFLD, T2DM, Renal diseases, Alcohol, Obesity

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) is independently associated with with prevalent as well as incident cardiovascular diseases (CVD), type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and Metabolic syndrome (MetS). Awareness of Renal Morbidity and full understanding is work at progress. Hence it was determined to assess the Renal morbidity as measured by eGFR in patients of T2DM with and without NAFLD.

Methods: Patients with T2DM (ICMR 2018 criteria) with proper informed and valid consent and satisfying essential inclusion and exclusion criteria were screened for presence of fatty liver by ultrasound and were divided into two groups; those with NAFLD and without NAFLD. All patients were investigated for renal morbidity in terms of eGFR using MDRD formula.

Result: Diabetic patients with NAFLD had lower eGFR levels compared to diabetics without NAFLD (p<0.05). Patients with diabetes and NAFLD has significantly higher BMI, WHR, duration of diabetes compared to Diabetes patients without NAFLD.

Conclusions: Group of diabetics with NAFLD have to be closely monitoring for serum creatinine levels and BMI is required for early intervention and optimisation of treatment. Elderly patients required more prompt monitoring.

Metrics

Metrics Loading ...

References

Rinella M, Charlton M. The globalization of non-alcoholic fatty liver disease: Prevalence and impact on world health. Hepatology (Baltimore, Md.). 2016;64(1):19-22.

Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature Reviews. Gastroenterol Hepatol. 2013;10(6):330-44.

Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of nonalcoholic fatty liver disease (NAFLD). Metabol Clin xperimental. 2016;65(8):1038-48.

Caldwell SH, Argo CK. Non-alcoholic fattyliver disease; in Clinical Dilemmas in non alcoholic fatty liver Disease. Chichester, John Wiley and Sons, Ltd. 2016;1-7.

Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29(3):664-9.

Cao Y, Deng Y, Wang J, Zhao H, Zhang J, Xie W. The association between NAFLD and risk of chronic kidney disease: a cross-sectional study. Therapeutic Advances in Chronic Disease. 2021;12:20406223211048649.

Marcuccilli M, Chonchol M. NAFLD and chronic kidney disease. Int J Mole Sci. 2016;17(4):562.

Mantovani A. Non-alcoholic fatty liver disease and risk of developing chronic kidney disease: a new piece of a recent puzzle from a large Asian study. AMJ. 2018;2:2.

Mohan V, Deepa R, Rani SS. Chennai Urban Population Study (CUPS No. 5) Prevalence of coronary artery disease and its relationship to lipids in selected population in South India: Chennai Urban Population study. J Am Coll Cardiol. 2001;38(3):682-7.

Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013;382(9888):260– 272. doi:10.1016/s01406736(13)60687-x.

Stanifer JW, Kilonzo K, Wang D, Su G, Mao W, Zhang L et al. Traditional medicines and kidney disease in low- and middle-income countries: opportunities and challenges. Semin Nephrol. 2017;37(3):245-59.

Musso G, Cassader M, Cohney S, Pinach S, Saba F, Gambino R. Emerging liver-kidney interactions in non-alcoholic fatty liver disease. Trends Mol Med. 2015;21(10):645-62.

Dai W, Ye L, Liu A, Wen SW, Deng J, Wu X et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Medicine. 2017;96(39):e8179.

Gomercić M, Duvnjak M, Barsić N. Ultrasonography in the diagnosis of nonalcoholic fatty liver disease. Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti. 2009;63:1-3.

Fan R, Wang J, Du J. Association between body mass index and fatty liver risk: a dose-response analysis. Scientific Rep. 2018;8(1):1-7.

Khan A, Ross HM, Parra NS, Chen SL, Chauhan K, Wang M et al. Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD). Livers. 2022;2(4):264-82.

Lin MS, Lin TH, Guo SE, Tsai MH, Chiang MS, Huang TJ et al. Waist-to-height ratio is a useful index for non-alcoholic fatty liver disease in children and adolescents: a secondary data analysis. BMC Pub Heal. 2017;17(1):1-8.

Chinnadurai R, Ritchie J, Green D, Kalra PA. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Nephrology dialysis transplantation. 2019;34(3):449-57.

Hsieh MH, Wu KT, Chen YY, Yang JF, Lin WY, Chang NC et al. Higher NAFLD fibrosis score is associated with impaired eGFR. J Formosan Med Asso. 2020;119(1):496-503

Al-Ozairi E, Jallo MK, Hafidh K, Alhajeri DM, Ashour T, Mahmoud EF et al. Prevalence of cardiovascular and renal co-morbidities in patients with type 2 diabetes in the Gulf, a cross-sectional observational study. Diabetes Therapy. 2021;12(4):1193-207.

Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72(4):785-801.